New combo therapy targets Hard-to-Treat prostate cancer

NCT ID NCT07316686

Not yet recruiting Disease control Sponsor: Instituto do Cancer do Estado de São Paulo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a combination of two drugs—docetaxel (chemotherapy) and a radioactive compound called 177Lu-PSMA-I&T—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose of docetaxel when used with the radioactive drug. Only 18 men will take part, and the study focuses on side effects and tolerability, not yet on how well the treatment works against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: docetaxel and 177Lu-PSMA-I&T (a radioactive drug that targets prostate cancer cells)
What this could lead to: If this works, it could point toward a more effective first-line treatment for advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is a very early Phase I trial with only 18 participants, so it is primarily testing safety and dosing. It is too small to prove whether the combination actually improves outcomes, and side effects from the chemotherapy and radiation could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Locations

Instituto do Câncer do Estado de São Paulo - ICESP

São Paulo, 01246000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.